FAM13A polymorphism is associated with a usual interstitial pneumonia pattern in patients with systemic sclerosis-associated interstitial lung disease

被引:0
|
作者
Bernstein, Elana J. [1 ]
Boin, Francesco [2 ]
Elicker, Brett [3 ]
Luo, Yiming [1 ]
Ren, Yawen [4 ]
Zhang, Meng [5 ]
Varga, John [6 ]
Assassi, Shervin [5 ]
机构
[1] Columbia Univ, Irving Med Ctr, Vagelos Coll Phys & Surg, Dept Med,Div Rheumatol, New York, NY USA
[2] Cedars Sinai Med Ctr, Dept Med, Div Rheumatol, Los Angeles, CA USA
[3] Univ Calif San Francisco, Dept Radiol, San Francisco, CA USA
[4] Univ Colorado, Dept Med, Div Rheumatol, Denver, CO USA
[5] Univ Texas Hlth Sci Ctr Houston, UTHlth Houston, Dept Med, Div Rheumatol, Houston, TX USA
[6] Univ Michigan, Dept Internal Med, Div Rheumatol, Ann Arbor, MI USA
基金
美国国家卫生研究院;
关键词
systemic sclerosis; interstitial lung disease; usual interstitial pneumonia; FAM13A; MUC5B; IDIOPATHIC PULMONARY-FIBROSIS; PROMOTER POLYMORPHISM; SUSCEPTIBILITY; GENE; SCLERODERMA; LOCI;
D O I
10.1093/rheumatology/keae573
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: The MUC58 promoter single nucleotide polymorphism (SNP) rs35705950 has been associated with idiopathic pulmonary fibrosis (IPF) and RA-related interstitial lung disease (ILD), but not with SSc-ILD. We hypothesized that the MUC58 promoter polymorphism or other IPF susceptibility loci are associated with an increased risk for the uncommon SSc-usual interstitial pneumonia (UIP) endophenotype, rather than SSc-ILD in general. Methods: We performed a cross-sectional study of SSc-ILD patients from four US Scleroderma Programs to investigate the frequency of MUC58 rs35705950 and 12 additional IPF susceptibility loci. SSc-ILD patients were stratified by high resolution chest CT (HRCT) imaging findings into UIP and non-UIP groups. Analysis of HRCTs performed by a thoracic radiologist blinded to participants' characteristics classified each scan as definite UIP, probable UIP, indeterminate or alternative diagnosis, according to American Thoracic Society criteria. Results: Four-hundred and eighty-nine SSc-ILD patients were included; 80% were female and 75% were White. Twenty-three (4.7%) patients had a definite UIP pattern. The MUC58 SNP rs35705950 was not associated with a definite UIP pattern in SSc-ILD. In contrast, patients carrying two copies of the IPF risk gene FAM13A minor allele rs2609255 had significantly higher odds of a definite UIP pattern compared with the other patterns (odds ratio 3.40, 95% CI 1.19-9.70), and compared with an alternative diagnosis (odds ratio 3.65, 95% CI 1.25-10.65). Conclusion: We demonstrated a novel association between FAM13A and SSc-UIP. Contrary to IPF and RA-ILD, the MUC58 promoter polymorphism was not associated with a definite UIP pattern in SSc-ILD.
引用
收藏
页数:6
相关论文
共 50 条
  • [1] Systemic sclerosis-associated interstitial lung disease
    Scallan, Ciaran J.
    Collins, Bridget F.
    Raghu, Ganesh
    CURRENT OPINION IN PULMONARY MEDICINE, 2020, 26 (05) : 487 - 495
  • [2] Treatment of systemic sclerosis-associated interstitial lung disease
    Prasse, A.
    Bonella, F.
    Mueller-Ladner, U.
    Witte, T.
    Hunzelmann, N.
    Distler, J.
    ZEITSCHRIFT FUR RHEUMATOLOGIE, 2020, 79 (03): : 294 - 303
  • [3] Rituximab treatment for systemic sclerosis-associated interstitial lung disease: a case series of 13 patients
    Morgan, Kelly
    Woollard, Charlotte
    Beinart, Dylan
    Host, Lauren, V
    Roddy, Janet
    INTERNAL MEDICINE JOURNAL, 2023, 53 (07) : 1147 - 1153
  • [4] Treatment for systemic sclerosis-associated interstitial lung disease
    Roofeh, David
    Lescoat, Alain
    Khanna, Dinesh
    CURRENT OPINION IN RHEUMATOLOGY, 2021, 33 (03) : 240 - 248
  • [5] Personalized Medicine for Systemic Sclerosis-Associated Interstitial Lung Disease
    Ma, Angela
    Montesi, Sydney B.
    CURRENT TREATMENT OPTIONS IN RHEUMATOLOGY, 2025, 11 (01)
  • [6] Management of systemic sclerosis-associated interstitial lung disease
    Roofeh, David
    Jaafar, Sara
    Vummidi, Dharshan
    Khanna, Dinesh
    CURRENT OPINION IN RHEUMATOLOGY, 2019, 31 (03) : 241 - 249
  • [7] Nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease
    Yamasaki, Yoshioki
    Kuwana, Masataka
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2020, 16 (06) : 547 - 560
  • [8] Novel Imaging Approaches in Systemic Sclerosis-Associated Interstitial Lung Disease
    Montesi, Sydney B.
    Caravan, Peter
    CURRENT RHEUMATOLOGY REPORTS, 2019, 21 (06)
  • [9] Characteristics and risk factors of mortality in patients with systemic sclerosis-associated interstitial lung disease
    Jang, Hye Jin
    Woo, Ala
    Kim, Song Yee
    Yong, Seung Hyun
    Park, Youngmok
    Chung, Kyungsoo
    Lee, Su Hwan
    Leem, Ah Young
    Lee, Sang Hoon
    Kim, Eun Young
    Jung, Ji Ye
    Kang, Young Ae
    Kim, Young Sam
    Park, Moo Suk
    ANNALS OF MEDICINE, 2023, 55 (01) : 663 - 671
  • [10] Current treatment of systemic sclerosis-associated interstitial lung disease
    Bes, Cemal
    Cetinkaya, Erdogan
    TUBERKULOZ VE TORAKS-TUBERCULOSIS AND THORAX, 2022, 70 (01): : 85 - 92